le cd19  (Novus Biologicals)

Journal: Medecine sciences : M/S

Article Title: [Optimizing efficacy and security of CAR-T cells, and immune monitoring].

doi: 10.1051/medsci/2024058

Figure Lengend Snippet: Figure 3. Schéma d’un lentivirus CAR-T CD19. (selon BPS Bioscience, https://bps- bioscience.com/anti-cd19-car-lentivirus-cd19-scfv-cd8-4-1bb-cd3z-78600). LTR : long terminal repeat ; RRE : Rev-responsive element ; cPPT/CTS : central polypurine tract/central termination sequence ; IRES : IUnternal ribosome entry site ; PuroR : gène de résistance à la puromycine ; WPRE : Woodchuckhepatitis hirus posttranscriptional regulatory element ; 3’-UTR : 3’Untranslated region ; AmpR : gène de résistance à l’ampicilline ; VL et FL : chaînes légère et lourde des immunoglobulines, respectivement.

Article Snippet: 40, mai 2024 En France, le CAR CD19 (Yescarta®) est principalement utilisé.

Techniques: Sequencing

Journal: British Journal of Cancer

Article Title: Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors

doi: 10.1038/s41416-023-02235-9

Figure Lengend Snippet: a Representative images of each TLS maturation category, showing DCs (CD1c, light blue), CD4 T cells (CD4, yellow), CD8 T cells (CD8, orange), B cells (CD19, red), follicular DCs (CD21, green), plasma cells (CD138, purple) and DAPI. b Total cell counts in high-power field (HPF) based on TLS maturation category. c Composition of six immune cell subsets in TLSs according to each maturation category. d Proportion of CD138 + plasma cells in TLSs according to each maturation category. Scale bars = 200 µm. Comparisons were made by Mann–Whitney U test.

Article Snippet: The primary antibodies were anti-CD1c (mouse monoclonal, clone OTI2F4; Abcam, Cambridge, UK), anti-CD4 (mouse monoclonal, clone 4B12; Invitrogen, Waltham, USA), anti-CD8 (mouse monoclonal, clone C8/144b; DAKO, Glostrup, Denmark), anti-CD19 (mouse monoclonal, clone LE-CD19; Invitrogen, Waltham, USA), anti-CD21 (rabbit monoclonal, clone SP32; Abcam, Cambridge, UK), and anti-CD138 (mouse monoclonal, clone MI15; DAKO, Glostrup, Denmark).

Techniques: MANN-WHITNEY

Journal: Blood advances

Article Title: Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies.

doi: 10.1182/bloodadvances.2022007705

Figure Lengend Snippet: Figure 1. Emergence of a leukemic clone with a deletion of Tyr260 in CD19. (A) Diagnostic flow cytometry demonstrates loss of surface CD19 during treatment with

Article Snippet: In brief, after electrophoresis, membranes were blocked using 5% milk and subsequently stained with primary antibody mouse anti-human CD19 clone LE-CD19 (1:2000; Novus Biological) or rabbit antihuman glyceraldehyde-3-phosphate dehydrogenase clone D16H11 (1:2000; Cell Signaling Technologies).

Techniques: Diagnostic Assay, Cytometry

Journal: International Journal of Molecular Sciences

Article Title: High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade

doi: 10.3390/ijms23169124

Figure Lengend Snippet: Multispectral Immunofluorescence tissue imaging of good and bad responder cases. ( a , b ) Fluorescence panels images of the markers CD11b, CD68, CD3, CD8, CD20, MELAN-A in ( a ) and CD19, CD20 and C138 in ( b ) of the patient IMK-20 (bad responder) and IMK-38 (good responder). ( c ) Boxplot with the Wilcoxon test comparing the density (Cells/mm 2 ) between good and bad responders of CD8 and CD19.

Article Snippet: The melanoma-associated B-cells panel included: CD19 (Mouse monoclonal, clone LE-CD19, ready-to-use, Agilent, Santa Clara, CA 95051, USA, product number GA656), CD20 (Mouse monoclonal, IgG2α, clone L26, ready-to-use, Agilent, Santa Clara, CA 95051, USA, product number GA604), CD138 (Mouse monoclonal, IgG1, clone MI15, 1:100, Agilent, Santa Clara, CA 95051, USA, product number M7228).

Techniques: Immunofluorescence, Imaging, Fluorescence

Journal: Molecular cancer therapeutics

Article Title: Targeting TfR1 with the ch128.1/IgG1 antibody inhibits EBV driven lymphomagenesis in immunosuppressed mice bearing EBV + human primary B-cells

doi: 10.1158/1535-7163.MCT-21-0074

Figure Lengend Snippet: A, Representative flow cytometry plots of cells isolated from spleens of mice implanted with EBV− or EBV+ B-cell enriched preparations and treated with ch128.1/IgG1 or IgG1 control monoclonal antibody. Plots compare the percentage of murine CD45+ (mCD45+) and human CD45+ (hCD45+) cell populations (gated from live cells). Human CD3+ T-cell and CD19+ B-cell populations were gated from hCD45+ cells. B, Percentage of hCD45+ cells in peripheral blood, spleen, lymph node, and liver tissues for each EBV+ group treated with ch128.1/IgG1 or IgG1 control. The bars represent mean values of %hCD45+ B-cells; EBV+ group treated with ch128.1/IgG1: peripheral blood mean = 0.7%, spleen mean = 2.4%, lymph node mean = 2.6%, liver mean = 4.4%; EBV+ group treated with IgG1 isotype control: peripheral blood mean = 4.5%, spleen mean = 9.3%, lymph node mean = 10.5%, liver mean = 7.3%. C, Percentage of hCD19+ B-cells in peripheral blood, spleen, lymph node, and liver tissues. Percentages of hCD19+ B-cells were calculated from the total percentage of hCD45+ cells for each sample [(percentage of hCD19+) × (percentage of hCD45+ / 100%)]. The bars represent mean values of %hCD19+ B-cells; EBV+ group treated with ch128.1/IgG1: peripheral blood mean = 0.4%, spleen mean = 1.2%, lymph node mean = 0.8%, liver mean = 1.2%; EBV+ group treated with IgG1 isotype control: peripheral blood mean = 3.3%, spleen mean = 6.4%, lymph node mean = 7.6%, liver mean = 4.8%. Combined results shown in B and C are from 2 independent experiments. The results shown here for the EBV+ group treated with IgG1 control are from 12 of the 14 mice presented in Fig. 1B as two mice died before acquiring tissue at necropsy. Statistical comparisons were made for ch128.1/IgG1 versus IgG1 control treatments using nonparametric, unpaired Mann-Whitney tests, where *p = 0.01–0.05, **p = 0.001–0.01, and ns, not significant.

Article Snippet: IHC was performed using the following antibodies: polyclonal rabbit anti-human Kappa (κ) Light Chain (Agilent, catalog no. A019102–2); polyclonal rabbit anti-human Lambda (λ) Light Chain (Agilent, catalog no. A019302–2); monoclonal mouse anti-Epstein-Barr Virus, LMP Clone CS.1–4 (Agilent, catalog no. M0897); polyclonal rabbit anti-human CD3 (Agilent, catalog no. GA50361–2); and monoclonal mouse anti-human CD19 (Clone LE-CD19) (Agilent, catalog no. M729629–2).

Techniques: Flow Cytometry, Isolation, MANN-WHITNEY

Journal: Molecular cancer therapeutics

Article Title: Targeting TfR1 with the ch128.1/IgG1 antibody inhibits EBV driven lymphomagenesis in immunosuppressed mice bearing EBV + human primary B-cells

doi: 10.1158/1535-7163.MCT-21-0074

Figure Lengend Snippet: Left panels, Human tonsil tissue showing positive staining for human CD19+ B-cells, human Ig κ or Ig λ LC, and EBV infection (EBV LMP1+). Middle panels, Representative IHC staining in liver tissue sections from mice implanted with EBV+ B-cell enriched preparations and treated with IgG1 control monoclonal antibody. This mouse had human CD19+ and EBV+ polyclonal tumor growths (derived from different EBV+ B-cell clones) in liver tissue (middle panels), and mesenteric lymph nodes (images of Mouse #2 are shown in Fig. 1D and IHC results are summarized in Table 1). Right panels, IHC staining in liver tissue sections from a mouse implanted with EBV+ B-cells and treated with IgG1 control. This mouse had tumor growths in liver (shown) and splenic tissue sections (not shown) that were of human CD19+ B-cell origin and EBV LMP1+, as summarized in Table 1. Liver cells were human Ig κ LC negative and Ig λ LC positive, suggesting that these were monoclonal lymphoproliferative growths.

Article Snippet: IHC was performed using the following antibodies: polyclonal rabbit anti-human Kappa (κ) Light Chain (Agilent, catalog no. A019102–2); polyclonal rabbit anti-human Lambda (λ) Light Chain (Agilent, catalog no. A019302–2); monoclonal mouse anti-Epstein-Barr Virus, LMP Clone CS.1–4 (Agilent, catalog no. M0897); polyclonal rabbit anti-human CD3 (Agilent, catalog no. GA50361–2); and monoclonal mouse anti-human CD19 (Clone LE-CD19) (Agilent, catalog no. M729629–2).

Techniques: Staining, Infection, Immunohistochemistry, Derivative Assay, Clone Assay

Journal: Molecular cancer therapeutics

Article Title: Targeting TfR1 with the ch128.1/IgG1 antibody inhibits EBV driven lymphomagenesis in immunosuppressed mice bearing EBV + human primary B-cells

doi: 10.1158/1535-7163.MCT-21-0074

Figure Lengend Snippet: Summary of IHC staining results for mice implanted with EBV + human B-cells and treated with IgG1 control monoclonal antibody that developed lymphoma-like growths.

Article Snippet: IHC was performed using the following antibodies: polyclonal rabbit anti-human Kappa (κ) Light Chain (Agilent, catalog no. A019102–2); polyclonal rabbit anti-human Lambda (λ) Light Chain (Agilent, catalog no. A019302–2); monoclonal mouse anti-Epstein-Barr Virus, LMP Clone CS.1–4 (Agilent, catalog no. M0897); polyclonal rabbit anti-human CD3 (Agilent, catalog no. GA50361–2); and monoclonal mouse anti-human CD19 (Clone LE-CD19) (Agilent, catalog no. M729629–2).

Techniques: Immunohistochemistry